source
- Axoltis reports Phase 2 failure of experimental ALS drug but notes small signalAxoltis Pharma, a French biotech, announced that its Phase 2 trial of an experimental ALS therapy did not meet its primary endpoints. The company said the data were noisy but observed a modest tre…
- Stakeholders call on FDA to set safety and treatment standards for emerging psychedelic therapiesAt a recent public hearing, experts and other stakeholders emphasized the need for clear safety and access guidelines as psychedelic medicines move closer to market. The FDA is intensifying effort…